Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,411 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Progressive Disease Clear all
Suspended Phase 2 Interventional

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

NCT00004999
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 3 Interventional

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

NCT00072215
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
cisplatin, ifosfamide, paclitaxel, vinblastine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
78
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

NCT01111604
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting No phase listed Observational

Sporadic Inclusion Body Myositis Natural History Study

NCT05046821
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

NCT00003348
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational

Language in Primary Progressive Aphasia

NCT00537004
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Oral Azacitidine, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
60
States / cities
Phoenix, Arizona • Burbank, California • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05425004
View directory record Official record
Conditions
Meningioma
Interventions
Cabozantinib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Early Phase 1 Interventional

Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine

NCT00867126
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
pioglitazone hydrochloride, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed Not applicable Interventional

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

NCT05866198
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Actigraph CP Insight Watch
Diagnostic Test
Lead sponsor
University of South Florida
Other
Eligibility
40 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

NCT07137871
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Avasopasem
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

NCT00485563
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

NCT00003465
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Pyroxamide in Treating Patients With Advanced Cancer

NCT00042900
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

NCT01348061
View directory record Official record
Conditions
Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 1 Interventional

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

NCT00880061
View directory record Official record
Conditions
Brain Neoplasm, Glioma
Interventions
IL13-PE38QQR
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 21, 2026, 11:10 AM EDT